Media coverage about Eagle Pharmaceuticals (NASDAQ:EGRX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 44.5596654573113 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Is Eagle Pharmaceuticals Inc (EGRX)’s Triple EMA Building Momentum? - Evergreen Caller (evergreencaller.com)
- Aralez Pharmaceuticals Inc. (ARLZ) is at $1.11 per share and Eagle … - Stocks Gallery (stocksgallery.com)
- Active Stocks on Watch: Eagle Pharmaceuticals Inc (EGRX) and Vanguard Small-Cap Index Fund (VB) - Stock Press Daily (stockpressdaily.com)
- Eagle Pharmaceuticals (EGRX) & Repligen Corporation (RGEN) Head-To-Head Comparison (americanbankingnews.com)
- Eagle Pharmaceuticals, Inc. (EGRX) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
EGRX has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Piper Jaffray Companies set a $118.00 price objective on shares of Eagle Pharmaceuticals and gave the stock an “overweight” rating in a research note on Tuesday, May 9th. Royal Bank of Canada boosted their price objective on shares of Eagle Pharmaceuticals from $86.00 to $94.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 9th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 16th. Finally, BidaskClub cut shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $75.40.
Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at 54.40 on Friday. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $97.15. The firm has a market capitalization of $825.19 million, a PE ratio of 9.13 and a beta of 1.31. The stock has a 50 day moving average of $61.24 and a 200-day moving average of $75.20.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by $0.18. The company had revenue of $50.10 million for the quarter, compared to analysts’ expectations of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. Eagle Pharmaceuticals’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.80 earnings per share. Equities analysts anticipate that Eagle Pharmaceuticals will post $3.61 earnings per share for the current fiscal year.
Eagle Pharmaceuticals declared that its Board of Directors has approved a stock buyback plan on Wednesday, August 9th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to purchase up to 13.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein acquired 20,400 shares of the stock in a transaction dated Wednesday, August 9th. The shares were acquired at an average cost of $49.07 per share, for a total transaction of $1,001,028.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Pete A. Meyers acquired 350 shares of the stock in a transaction dated Monday, June 12th. The stock was acquired at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now directly owns 350 shares of the company’s stock, valued at $25,021.50. The disclosure for this purchase can be found here. Insiders bought 21,100 shares of company stock worth $1,045,457 over the last 90 days. Company insiders own 19.50% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
